5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
| Autor: | Dieras, V., Glaspy, J., Brufsky, A., Bondarenko, I., Lipatov, O., Perez, E.A., Chan, S., Zhou, X., Phan, S.C., Robert, N. |
|---|---|
| Zdroj: | In EJC Supplements 2009 7(2):265-265 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect